FC
DFTX

Fore Capital’s Definium Therapeutics DFTX Stock Holding History

Fore Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$201K – 51
2025
Q4 		$201K Sell
15,000
-20,000
-57% -$248K 0.07% 49
2025
Q3 		$413K Hold
35,000
– – 0.12% 52
2025
Q2 		$227K Sell
35,000
-5,000
-13% -$32.9K 0.08% 34
2025
Q1 		$234K Buy
40,000
+2,461
+7% +$17.6K 0.14% 45
2024
Q4 		$261K Buy
37,539
+7,539
+25% +$51.9K 0.1% 45
2024
Q3 		$171K Buy
30,000
+15,000
+100% +$104K 0.07% 35
2024
Q2 		$108K Buy
+15,000
New +$131K 0.07% 43
2023
Q1 		– Sell
-47,999
Closed -$106K – 33
2022
Q4 		$106K Hold
47,999
– – 0.04% 34
2022
Q3 		$168K Buy
47,999
+37,332
+350% +$358K 0.21% 24
2022
Q2 		$102K Buy
10,667
+4,000
+60% +$50.6K 0.11% 31
2022
Q1 		$111K Buy
+6,667
New +$116K 0.05% 43

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fore Capital's DFTX Position: Q1 2026 in Review

Fore Capital sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 15,000 shares — an estimated $201K sold.

Fore Capital first reported a position in DFTX in Q1 2022 and held it in 11 quarters. The position peaked at $413K in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Fore Capital reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fore Capital sold 15,000 Definium Therapeutics shares in Q1 2026, an estimated $201K.
  • Fore Capital first reported a position in Definium Therapeutics in Q1 2022 and held it in 11 quarters.
  • Fore Capital's Definium Therapeutics position peaked at $413K in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Fore Capital's 13F filing for Q1 2026, filed 8 May 2026.